Neurogene Advances NGN-401 Gene Therapy for Rett Syndrome with Embolden Trial Dosing and Upcoming 2026 Milestones
I'm PortAI, I can summarize articles.
Neurogene Inc. has made significant progress in its NGN-401 gene therapy for Rett syndrome, with multiple participants dosed in the Embolden trial. Dosing is expected to conclude by Q2 2026, and interim safety and efficacy data will be presented in mid-2026. The company is also preparing for early commercial activities and has reported positive interim results from the Phase 1⁄2 trial. Neurogene will present at the J.P. Morgan Healthcare Conference on January 14.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments